Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Zymeworks Inc.

< Previous 1 2 3 4 Next >
Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks to Transfer Stock Listing to Nasdaq
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conference
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks to Host Third Quarter Results Conference Call
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Completes Plan to Become Delaware Corporation
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Results of Special Meeting
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks to Host Second Quarter Results Conference Call
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Plan to Become a Delaware Corporation
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conference
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.